The pro-regenerative effects of HyperIL6 in drug induced liver injury are unexpectedly due to competitive inhibition of IL11 signaling

  1. Jinrui Dong
  2. Sivakumar Viswanathan
  3. Eleonora Adami
  4. Sebastian Schafer
  5. Fathima F Kuthubudeen
  6. Anissa A Widjaja
  7. Stuart A Cook  Is a corresponding author
  1. Duke-National University of Singapore Medical School, Singapore
  2. National Heart Research Institute of Singapore, Singapore

Abstract

It is generally accepted that IL6-mediated STAT3 signaling in hepatocytes, mediated via glycoprotein 130 (gp130; IL6ST), is beneficial and that the synthetic IL6:IL6ST fusion protein (HyperIL6) promotes liver regeneration. Recently, autocrine IL11 activity that also acts via IL6ST but uses ERK rather than STAT3 to signal, was found to be hepatotoxic. Here we examined whether the beneficial effects of HyperIL6 could reflect unappreciated competitive inhibition of IL11-dependent IL6ST signaling. In human and mouse hepatocytes, HyperIL6 reduced N-acetyl-p-aminophenol (APAP)-induced cell death independent of STAT3 activation and instead, dose-dependently, inhibited IL11-related signaling and toxicities. In mice, expression of HyperIl6 reduced ERK activation and promoted STAT3-independent hepatic regeneration (PCNA, Cyclin D1, Ki67) following administration of either IL11 or APAP. Inhibition of putative intrinsic IL6 trans-signaling had no effect on liver regeneration in mice. Following APAP, mice deleted for Il11 exhibited spontaneous liver repair but HyperIl6, despite robustly activating STAT3, had no effect on liver regeneration in this strain. These data show that synthetic IL6ST binding proteins such as HyperIL6 can have unexpected, on-target effects and suggest IL11, not IL6, as important for liver regeneration.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data are provided with this paper.

Article and author information

Author details

  1. Jinrui Dong

    Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore, Singapore
    Competing interests
    No competing interests declared.
  2. Sivakumar Viswanathan

    Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore, Singapore
    Competing interests
    No competing interests declared.
  3. Eleonora Adami

    Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore, Singapore
    Competing interests
    No competing interests declared.
  4. Sebastian Schafer

    Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore, Singapore
    Competing interests
    Sebastian Schafer, is a co-inventor of the patent applications: WO/2017/103108 (Treatment of Fibrosis), WO/2018/109174 (IL11 Antibodies), WO/2018/109170 (IL11RA Antibodies), and US 2020/0262910 (Treatment of Hepatotoxicity). Is a co-founder and shareholder of Enleofen Bio PTE LTD..
  5. Fathima F Kuthubudeen

    Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore, Singapore
    Competing interests
    No competing interests declared.
  6. Anissa A Widjaja

    Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore, Singapore
    Competing interests
    Anissa A Widjaja, A.A.W is a co-inventor of the patent application: US 2020/0262910 (Treatment of Hepatotoxicity)..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9404-7608
  7. Stuart A Cook

    CVMD, National Heart Research Institute of Singapore, Singapore, Singapore
    For correspondence
    stuart.cook@duke-nus.edu.sg
    Competing interests
    Stuart A Cook, S.A.C. is a co-inventor of the patent applications: WO/2017/103108 (TREATMENT OF FIBROSIS), WO/2018/109174 (IL11 ANTIBODIES), WO/2018/109170 (IL11RA ANTIBODIES), and US 2020/0262910 (Treatment of Hepatotoxicity). S.A.C. is a co-founder and shareholder of Enleofen Bio PTE LTD..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6628-194X

Funding

National Medical Research Council (NMRC/STaR/0029/2017)

  • Stuart A Cook

National Medical Research Council (NMRC Centre Grant to the NHCS)

  • Stuart A Cook

National Medical Research Council (MOH‐CIRG18nov‐0002)

  • Stuart A Cook

Medical Research Council (MRC-LMS)

  • Stuart A Cook

Goh Foundation

  • Stuart A Cook

Tanoto Foundation

  • Stuart A Cook

National Medical Research Council (NMRC/OFYIRG/0053/2017)

  • Anissa A Widjaja

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Animal studies were carried out in compliance with the recommendations in the Guidelines on the Care and Use of Animals for Scientific Purposes of the National Advisory Committee for Laboratory Animal Research (NACLAR). All experimental procedures were approved (SHS/2014/0925 and SHS/2019/1482) and conducted in accordance with the SingHealth Institutional Animal Care and Use Committee.

Copyright

© 2021, Dong et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,358
    views
  • 257
    downloads
  • 9
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jinrui Dong
  2. Sivakumar Viswanathan
  3. Eleonora Adami
  4. Sebastian Schafer
  5. Fathima F Kuthubudeen
  6. Anissa A Widjaja
  7. Stuart A Cook
(2021)
The pro-regenerative effects of HyperIL6 in drug induced liver injury are unexpectedly due to competitive inhibition of IL11 signaling
eLife 10:e68843.
https://doi.org/10.7554/eLife.68843

Share this article

https://doi.org/10.7554/eLife.68843

Further reading

    1. Cell Biology
    Joan Chang, Adam Pickard ... Karl E Kadler
    Research Article

    Collagen-I fibrillogenesis is crucial to health and development, where dysregulation is a hallmark of fibroproliferative diseases. Here, we show that collagen-I fibril assembly required a functional endocytic system that recycles collagen-I to assemble new fibrils. Endogenous collagen production was not required for fibrillogenesis if exogenous collagen was available, but the circadian-regulated vacuolar protein sorting (VPS) 33b and collagen-binding integrin α11 subunit were crucial to fibrillogenesis. Cells lacking VPS33B secrete soluble collagen-I protomers but were deficient in fibril formation, thus secretion and assembly are separately controlled. Overexpression of VPS33B led to loss of fibril rhythmicity and overabundance of fibrils, which was mediated through integrin α11β1. Endocytic recycling of collagen-I was enhanced in human fibroblasts isolated from idiopathic pulmonary fibrosis, where VPS33B and integrin α11 subunit were overexpressed at the fibrogenic front; this correlation between VPS33B, integrin α11 subunit, and abnormal collagen deposition was also observed in samples from patients with chronic skin wounds. In conclusion, our study showed that circadian-regulated endocytic recycling is central to homeostatic assembly of collagen fibrils and is disrupted in diseases.

    1. Cell Biology
    Chun-Wei Chen, Jeffery B Chavez ... Bruce J Nicholson
    Research Article Updated

    Endometriosis is a debilitating disease affecting 190 million women worldwide and the greatest single contributor to infertility. The most broadly accepted etiology is that uterine endometrial cells retrogradely enter the peritoneum during menses, and implant and form invasive lesions in a process analogous to cancer metastasis. However, over 90% of women suffer retrograde menstruation, but only 10% develop endometriosis, and debate continues as to whether the underlying defect is endometrial or peritoneal. Processes implicated in invasion include: enhanced motility; adhesion to, and formation of gap junctions with, the target tissue. Endometrial stromal (ESCs) from 22 endometriosis patients at different disease stages show much greater invasiveness across mesothelial (or endothelial) monolayers than ESCs from 22 control subjects, which is further enhanced by the presence of EECs. This is due to the enhanced responsiveness of endometriosis ESCs to the mesothelium, which induces migration and gap junction coupling. ESC-PMC gap junction coupling is shown to be required for invasion, while coupling between PMCs enhances mesothelial barrier breakdown.